{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-05-06",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Ongoing",
      "city": "Irvine",
      "state": "CA",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Devices",
      "event_id": "98475",
      "recalling_firm": "Beta Bionics, Inc.",
      "address_1": "11 Hughes",
      "address_2": "",
      "postal_code": "92618-1902",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "",
      "distribution_pattern": "US Nationwide distribution in the states of TX, PA, AL, MI, OH, FL, TN, GA.",
      "recall_number": "Z-1996-2026",
      "product_description": "iLet Bionic Pancreas, REF: BB1001",
      "product_quantity": "1,080",
      "reason_for_recall": "insulin pump software versions 1.4.2, and 1.4.3 issue with Dexcom Continuous  Glucose Monitoring (CGM) G7 sensor may result in delayed CGM reading then switch to non-CGM dosing, leading to only basal/requested meal doses provided, no correction doses/insulin reductions/suspensions for high/low glucose unless blood glucose entered for  sensor life or replacement. Potential health risks to users include severe hyperglycemia with and without DKA and severe hypoglycemia.",
      "recall_initiation_date": "20260312",
      "center_classification_date": "20260429",
      "report_date": "20260506",
      "code_info": "Software versions 1.4.3, and 1.4.2",
      "more_code_info": ""
    }
  ]
}